C4 Therapeutics (CCCC) Cash from Financing Activities (2019 - 2026)

C4 Therapeutics has reported Cash from Financing Activities for 8 years, with the latest figure at $462000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 1104.35% year-over-year to $462000.0; the trailing twelve-month figure through Mar 2026 stood at $126.9 million (up 1085.27% YoY), and the FY2025 full-year result was $126.4 million, up 178.8% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $462000.0, down from $118.7 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $118.7 million in Q4 2025, with the low at -$10.8 million in Q3 2023.
• Average Cash from Financing Activities over 5 years is $13.7 million, with a median of $310000.0 recorded in 2022.
• Peak annual rise in Cash from Financing Activities reached 122606.38% in 2023, while the deepest fall reached 3078.67% in 2023.
• Tracing CCCC's Cash from Financing Activities over 5 years: stood at $47000.0 in 2022, then jumped by 122606.38% to $57.7 million in 2023, then tumbled by 99.81% to $112000.0 in 2024, then soared by 105857.14% to $118.7 million in 2025, then sank by 99.61% to $462000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $462000.0 (Q1 2026), $118.7 million (Q4 2025), and $7.8 million (Q3 2025), per Business Quant data.

Peer Comparison